NCT05266768 is a Phase 1 clinical trial of IBI346 in Relapsed/Refractory Multiple Myeloma, sponsored by Chunrui Li.

Who is sponsoring NCT05266768?

NCT05266768 is sponsored by Chunrui Li.

What drugs are being tested in NCT05266768?

Interventions in NCT05266768: IBI346.

What condition does NCT05266768 study?

NCT05266768 studies Relapsed/Refractory Multiple Myeloma.

Is NCT05266768 still recruiting?

NCT05266768 is currently status unknown. Last updated 30 November 2022.

Last reviewed 2022-11-30 · How we verify

NCT05266768

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#

Status unknown Phase 1 Last updated 30 November 2022

What this trial tests

Phase 1 trial testing IBI346 in Relapsed/Refractory Multiple Myeloma in 36 participants. Status unknown.

Timeline

28 April 2022

Primary endpoint
28 February 2024

28 February 2024

Quick facts

Lead sponsor	Chunrui Li
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	28 April 2022
Primary completion	28 February 2024
Estimated completion	28 February 2024
Sites	1 location across China

Drugs / interventions tested

IBI346 — full drug profile →

Conditions studied

Relapsed/Refractory Multiple Myeloma — all drugs for Relapsed/Refractory Multiple Myeloma →

Sponsor

Chunrui Li — full company profile →

Who can join

18 and older, any sex, with Relapsed/Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An open label, single-arm clinical study evaluating the safety and efficacy of IBI346 infusion in relapsed/refractory multiple myeloma

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
Shrivastava T, Van Rhee F, Al Hadidi S. · · 2023 · cited 10× · PMID 37359353 · DOI 10.2147/ott.s370880
The Current Landscape of Modular CAR T Cells.
Joechner AH, Mach M, Li Z. · · 2025 · PMID 41465327 · DOI 10.3390/ijms262411898
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.
Surowka M, Darowski D, Hutter-Karakoc I, Claus C, et al · · 2026 · PMID 41402230 · DOI 10.1080/19420862.2025.2602993
P1406: SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES
Fu C, LI C, Wang D, Jin S, et al · · 2023

Verify or expand the search:

Other trials of IBI346

Trials testing the same drug.

NCT05270928 — Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# · Phase 1 · completed

Other recruiting trials for Relapsed/Refractory Multiple Myeloma

Currently open trials in the same condition.

NCT07493135 — A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
NCT07509086 — IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia · Phase 2 · recruiting
NCT06730256 — A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia · EARLY_PHASE1 · recruiting
NCT06669247 — A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants · Phase 1, PHASE2 · recruiting
NCT06718270 — a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia · EARLY_PHASE1 · recruiting

Other Chunrui Li trials

Trials by the same sponsor.

NCT06791681 — A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
NCT05219721 — A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia · Phase 1 · recruiting
NCT05201118 — A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extram · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05266768 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chunrui Li
Last refreshed: 30 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05266768.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing